title: How to explain the reduced cardiovascular mortality in the ticagrelor arm of the PLATO trial?
authors.affiliation: Department of Cardiovascular Diseases, Azienda Ospedaliera Ospedale Civile di Legnano, Legnano, Italy. Electronic address: stefano.deservi@ao-legnano.it.
authors.forename: Stefano
authors.initials: S
authors.lastname: De Servi
authors.affiliation: Department of Cardiology, Ospedale Niguarda Ca' Granda, Milan, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Savonitto
mesh_terms: D000241:Adenosine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000401:mortality*; D002986:Clinical Trials as Topic / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000627:therapeutic use*; D000077486:Ticagrelor; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D000077486:Ticagrelor; D000241:Adenosine